Cargando…

Lessons from a cardiovascular outcome trial with liraglutide in type 2 diabetes

Detalles Bibliográficos
Autores principales:	Kim, Hae Jin, Kim, Dae Jung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497034/ https://www.ncbi.nlm.nih.gov/pubmed/27930863 http://dx.doi.org/10.1111/jdi.12607

Ejemplares similares

Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial
por: Kalra, Sanjay
Publicado: (2016)

Cardiovascular outcomes of liraglutide in patients with type 2 diabetes: A systematic review and meta-analysis
por: Duan, Chun-Mei, et al.
Publicado: (2019)

Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials
por: Tanaka, Atsushi, et al.
Publicado: (2018)

Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits
por: McGuire, Darren K., et al.
Publicado: (2021)

Urinary adiponectin and progression of diabetic nephropathy in type 1 diabetes
por: Ha, Kyoung Hwa, et al.
Publicado: (2015)

Liraglutide in the management of type 2 diabetes
por: Wajcberg, Estela, et al.
Publicado: (2010)

Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk
por: Huang, Wan-Chun, et al.
Publicado: (2021)

A randomized controlled trial protocol of the cardiovascular safety and efficacy of liraglutide in the treatment of type 2 diabetes
por: Liang, Ying, et al.
Publicado: (2021)

Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE
por: Liang, Bo, et al.
Publicado: (2020)

Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)
por: Lind, Marcus, et al.
Publicado: (2015)

Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group
por: Schnell, Oliver, et al.
Publicado: (2017)

Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial
por: Crowley, Matthew J., et al.
Publicado: (2020)

PDM-ProValue meets cardiovascular outcome trials in diabetes
por: Fritzen, Katharina, et al.
Publicado: (2019)

Intensive risk factor management and cardiovascular autonomic neuropathy in type 2 diabetes in the Action to Control Cardiovascular Risk in Diabetes trial: A post‐hoc analysis
por: Aso, Yoshimasa
Publicado: (2021)

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
por: Howell, Rebecca, et al.
Publicado: (2019)

Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
por: Schnell, Oliver, et al.
Publicado: (2016)

Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
por: Schnell, Oliver, et al.
Publicado: (2018)

Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
por: Schnell, Oliver, et al.
Publicado: (2019)

Pragmatic trials can address diagnostic controversies: recent lessons from gestational diabetes
por: Raymond, Jean, et al.
Publicado: (2022)

Potential of liraglutide in the treatment of patients with type 2 diabetes
por: Deacon, Carolyn F
Publicado: (2009)

Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
por: Rigato, Mauro, et al.
Publicado: (2014)

Impacts of tight multifactorial intervention in patients with type 2 diabetes: Implications from the Japan Diabetes Outcome Intervention Trial 3
por: Araki, Eiichi, et al.
Publicado: (2018)

Liraglutide and Glycaemic Outcomes in the LEADER Trial
por: Zinman, Bernard, et al.
Publicado: (2018)

LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations
por: Daniels, G H, et al.
Publicado: (2015)

Safety and Efficacy of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
por: Vemulapalli, Hema Srikanth, et al.
Publicado: (2023)

Cardiovascular disease in patients with type 2 diabetes
por: Jeon, Ja Young, et al.
Publicado: (2022)

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial
por: Mann, Johannes F. E., et al.
Publicado: (2018)

The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
por: Ehlers, Lars Holger, et al.
Publicado: (2021)

Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?
por: Schernthaner, Guntram, et al.
Publicado: (2018)

Mechanical ventilation: lessons from the ARDSNet trial
por: Slutsky , Arthur S, et al.
Publicado: (2000)

Liraglutide exhibits anti-inflammatory activity through the activation of the PKA/CREB pathway
por: Wang, Li, et al.
Publicado: (2019)

Epigenetic regulation of core genes linking to diabetic nephropathy progression: Lesson from FinnDiane type 1 diabetes study
por: Makino, Hirofumi, et al.
Publicado: (2023)

Report from the 5th cardiovascular outcome trial (CVOT) summit
por: Schnell, Oliver, et al.
Publicado: (2020)

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
por: Neumiller, Joshua J, et al.
Publicado: (2010)

Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs
por: Sjöholm, Åke
Publicado: (2010)

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
por: Jacobsen, Lisbeth V., et al.
Publicado: (2015)

Effect of liraglutide on expression of inflammatory genes in type 2 diabetes
por: Zobel, Emilie H., et al.
Publicado: (2021)

The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes
por: Zhao, Na, et al.
Publicado: (2021)

The importance of improving health literacy to lower cardiovascular risk in type 2 diabetes
por: Hansen, Dominique, et al.
Publicado: (2019)

Commentary: Lessons from the National Lung Screening Trial
por: Raymond, Daniel P.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0ta4f4qmmlqatb36avcd07ks2r